In the realm of aging research, the molecule nicotinamide adenine dinucleotide (NAD⁺) has long been heralded as a critical biomarker, often linked to cellular health, longevity, and metabolic vitality. NAD⁺ is a central coenzyme in redox reactions, essential for energy metabolism and DNA repair, and previous studies have suggested that its levels diminish with age, consequently contributing to age-associated functional decline. However, despite the popularity of this hypothesis, concrete evidence, especially in humans, has been inconsistent and fragmented. Now, a groundbreaking study published in Nature Metabolism challenges the entrenched dogma by revealing that NAD⁺ levels in human whole blood remain remarkably stable throughout the human lifespan and are surprisingly unresponsive to common lifestyle interventions.
This extensive investigation employed an ultra-high-performance liquid chromatography system coupled with high-resolution mass spectrometry, a methodologically rigorous approach that ensures precise quantification of NAD⁺ while accounting for real-world analytical variability. Prior attempts to quantify NAD⁺ levels in blood suffered from methodological limitations—low sensitivity, poor reproducibility, and the inability to fully control for confounding factors—which may have fueled controversies and discrepant results across cohorts. In contrast, the analytical refinement in this study sets a new gold standard for NAD⁺ measurement, enabling unprecedented clarity on its behavior within diverse human populations.
Seven independent human cohorts participated in this study, encompassing a broad spectrum of ages as well as various lifestyle backgrounds. By analyzing these distinct groups, the investigators sought to dissect whether NAD⁺ concentrations decline naturally with age or fluctuate in response to lifestyle factors such as diet, exercise, or supplementation. Remarkably, their data indicate a consistent stability of NAD⁺ levels in whole blood across decades of the human lifespan. This finding alone upends the prevailing notion that systemic NAD⁺ depletion is an inevitable hallmark of aging, suggesting instead that the blood compartment may maintain NAD⁺ homeostasis far better than previously appreciated.
The study further delved into how lifestyle interventions might influence NAD⁺ concentrations. Whereas certain nutritional or physical regimens are thought to impact metabolic health and potentially raise NAD⁺ levels, the results from these cohorts demonstrate negligible changes in blood NAD⁺ after such interventions. This challenges the belief that lifestyle modifications significantly modulate circulating NAD⁺ pools in humans, at least within the parameters and durations examined.
One of the few scenarios in which NAD⁺ levels in blood exhibited a marked shift was following supplementation with nicotinamide riboside (NR), a known NAD⁺ precursor. NR supplementation resulted in the expected elevation of NAD⁺ concentrations, affirming the assay’s sensitivity and the biological plausibility that exogenous precursors can boost systemic NAD⁺ availability. This pharmacological intervention thus serves as an important positive control within the study, validating their findings and underscoring the specificity of the stability observed under natural aging and lifestyle contexts.
Collectively, these findings raise profound questions about the appropriateness of using blood NAD⁺ levels as a biomarker of aging or as a surrogate to monitor lifestyle efficacy. If NAD⁺ is indeed maintained robustly in the bloodstream, it might reflect that whole-blood NAD⁺ is buffered by intricate cellular and systemic mechanisms. Such mechanisms may include compartment-specific NAD⁺ pools, tissue-specific dynamics, and regulatory feedback loops that are not fully mirrored in peripheral blood measurements.
This study also highlights the complexity of NAD⁺ metabolism. NAD⁺ participates in a variety of intracellular processes, including sirtuin activation, poly(ADP-ribose) polymerase (PARP) activity, and calcium signaling. Therefore, a decline at the tissue or cellular level may coexist with stable systemic levels, especially in blood. The authors posit that local NAD⁺ depletion relevant to aging and disease might not be captured by simply measuring whole-blood NAD⁺, necessitating refined biomarkers or imaging techniques capable of resolving NAD⁺ dynamics at higher resolution.
Another critical implication of this work relates to the burgeoning market for NAD⁺-boosting supplements, often marketed for anti-aging benefits. While the evident increase in NAD⁺ upon NR supplementation confirms that levels can be pharmacologically elevated, the physiological relevance and long-term outcomes of such increases remain to be elucidated. This study suggests that without clear evidence of age- or lifestyle-associated NAD⁺ deficiency in blood, claims about widespread NAD⁺ depletion and its reversal should be tempered by rigorous scientific validation.
Furthermore, the investigators emphasize the importance of methodological rigor and standardization in the assessment of NAD⁺ levels. Variability in sample handling, processing, and assay conditions can profoundly affect results, which may partly explain conflicting reports on NAD⁺ dynamics in prior literature. By employing their highly validated assay, they establish a benchmark for future research, enabling comparability and reproducibility across studies—a crucial step toward consensus in this evolving field.
This comprehensive inquiry not only reframes our understanding of NAD⁺ biology in humans but also invites deeper exploration into tissue-specific processes and how they relate to systemic NAD⁺ pools. It encourages researchers to question assumptions about biomarkers and to focus on nuanced, context-dependent mechanisms of aging and metabolism. Going forward, the development of novel technologies to measure NAD⁺ in situ within tissues and cells will be pivotal to unravel the complexities underlying age-related decline.
Importantly, the study also opens up avenues for reevaluating how lifestyle and environmental factors intersect with cellular metabolism. The absence of NAD⁺ fluctuation upon lifestyle modifications in blood underscores the resilience of metabolic homeostasis, yet does not negate potential benefits of lifestyle factors on other metabolic or epigenetic parameters influencing healthspan and longevity.
In conclusion, the work of Trętowicz et al. represents a landmark contribution to metabolic aging research, debunking the simplistic view of blood NAD⁺ as a declining biomarker with age or lifestyle. It pivots the spotlight toward understanding metabolic resilience and compartmentalization, refining how we approach therapeutic interventions and biomarker development for aging and metabolic diseases. This paradigm shift beckons a more sophisticated appreciation of NAD⁺’s role—one that balances biochemical nuance with clinical ambition.
As we advance into an era of precision medicine, these insights highlight the necessity for integrated approaches combining systemic measurements with tissue-level analyses to fully capture the biological narratives of aging. The findings underscore a critical principle in aging biology: not all established biochemical markers behave uniformly across compartments, and the search for reliable biomarkers demands stringent analytical precision coupled with biological nuance.
The scientific community and the public alike should regard this study as a clarion call to revisit assumptions about metabolic decline, to invest in high-quality methodologies, and to adopt a discerning eye toward the claims proliferating in nutritional and anti-aging domains. Future research catalyzed by this pioneering work will no doubt enrich our understanding of aging and inform the design of targeted interventions rather than blanket assumptions about molecular decline.
In sum, this meticulously executed multi-cohort study decisively clarifies that human whole-blood NAD⁺ levels do not decrease with age nor significantly vary with lifestyle interventions, except for the notable effect of nicotinamide riboside supplementation. It marks an important step forward in demystifying NAD⁺ biology and realigning expectations around its measurement and interpretation in human aging.
Subject of Research: Human whole-blood NAD⁺ levels variation with age and lifestyle interventions.
Article Title: Human whole-blood NAD⁺ levels do not vary with age or lifestyle interventions.
Article References:
Trętowicz, M.M., Scantlebery, A.M.L., Schomakers, B.V. et al. Human whole-blood NAD⁺ levels do not vary with age or lifestyle interventions. Nat Metab (2026). https://doi.org/10.1038/s42255-026-01537-5
Image Credits: AI Generated
